Integrated Wealth Concepts’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.93M Sell
11,257
-82
-0.7% -$46K 0.04% 420
2026
Q1
$6.37M Buy
11,339
+10,966
+2,940% +$7.03M 0.05% 352
2025
Q4
$253K Sell
373
-12,730
-97% -$8.67M ﹤0.01% 1398
2025
Q3
$8.37M Sell
13,103
-1,542
-11% -$936K 0.07% 253
2025
Q2
$7.85M Buy
14,645
+4,862
+50% +$2.32M 0.08% 238
2025
Q1
$4.11M Buy
9,783
+73
+0.8% +$31.7K 0.05% 360
2024
Q4
$4.01M Buy
+9,710
New +$4.26M 0.05% 338
2022
Q1
Sell
-322
Closed -$212K 999
2021
Q4
$212K Buy
+322
New +$202K 0.01% 915
2021
Q3
Sell
-701
Closed -$443K 964
2021
Q2
$443K Sell
701
-15
-2% -$8.28K 0.02% 555
2021
Q1
$350K Buy
716
+82
+13% +$41.1K 0.01% 551
2020
Q4
$317K Buy
634
+35
+6% +$15.7K 0.02% 506
2020
Q3
$235K Buy
+599
New +$221K 0.01% 510

Other funds holding IDXX

Integrated Wealth Concepts's IDXX Position: Q2 2026 in Review

Integrated Wealth Concepts reduced its Idexx Laboratories (IDXX) stake by 0.72% in Q2 2026, selling an estimated $46K and leaving 11,257 shares worth $5.93M. The position accounts for 0.04% of the portfolio, ranked #420.

Integrated Wealth Concepts first reported a position in IDXX in Q3 2020 and has held it in 12 quarters since. The position peaked at $8.37M in Q3 2025. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Integrated Wealth Concepts held 11,257 shares of Idexx Laboratories worth $5.93M as of Q2 2026.
  • Integrated Wealth Concepts sold 82 Idexx Laboratories shares in Q2 2026, an estimated $46K.
  • Idexx Laboratories made up 0.04% of Integrated Wealth Concepts's portfolio in Q2 2026, its #420 holding.
  • Integrated Wealth Concepts first reported a position in Idexx Laboratories in Q3 2020 and has held it in 12 quarters since.
  • Integrated Wealth Concepts's Idexx Laboratories position peaked at $8.37M in Q3 2025.
  • 1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.